Mesoblast
MESO | NASDAQ
$12.45
-$0.82 (-6.18%)
At close: Nov 16, 2026, 4:00 PM ET
$12.45
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:15 PM ET
Mesoblast Company Profile
Company profile explainedCompany Profile
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Key Executives
| Name | Position |
|---|---|
| Paul J. Simmons | Scientific Advisor to the Chief Executive Officer |
| Silviu Itescu FACP FACRA FRACP MBBS | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director |
| James Michael O'Brien | Chief Financial Officer |
| Anthony Wheal | Head of Human Resources |
| Daniel Devine | Head of Special Projects |
| Eric A. Rose | Chief Medical Officer & Executive Director |
| Fiona See | Senior Vice President & Head of Translational Research |
| Geraldine Storton | Head of Regulatory Affairs & Quality Management |
| Justin Horst | Head of Manufacturing |
| Marcelo Santoro | Chief Commercial Officer |
| Paul Hughes BPHARM | Global Head of Corporate Communications & Joint Company Secretary |
| Teresa Montagut | Head of Clinical Development & Medical Affairs |
Mesoblast
| Country | Australia |
| IPO Date | Jan 20, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Silviu Itescu |
Contact Details
55 Collins Street Melbourne,
VIC 3000 Australia
Stock Details
| Ticker Symbol | MESO |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001345099 |
| CUSIP Number | 590717401 |
| ISIN Number | US5907174016 |
| SIC Code | 2836 |
Recent News
- 1 day ago / globenewswire.comMesoblast Showcased at ASX Premier Investor Day Event
- 4 days ago / marketbeat.comMesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout
- 12 days ago / globenewswire.comUse Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
- 15 days ago / globenewswire.comMesoblast Board Changes
- 19 days ago / globenewswire.comActivity Report for Quarter Ended September 30, 2026 (Appendix 4C)
- 29 days ago / seekingalpha.comMesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain
- 2 months ago / globenewswire.comMesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
- 3 months ago / seekingalpha.comMesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
- 3 months ago / globenewswire.comMesoblast Reports Substantial Revenue Growth to US$120M
- 3 months ago / marketbeat.comMesoblast H2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove MESO